Phase I Results of Targeted Cancer Therapies from ASCO 2008
Author Information
Author(s): Andrea Molckovsky, Lillian Siu
Primary Institution: Princess Margaret Hospital, University of Toronto
Conclusion
The phase I trials of eleven first-in-human targeted agents showed promising results with acceptable toxicity and potential clinical efficacy.
Supporting Evidence
- Most drugs were well tolerated with no maximum tolerated dose reached for several agents.
- Clinical efficacy data showed that all drugs had at least some stable disease responders.
- Pharmacodynamic studies confirmed that the drugs targeted their intended pathways.
Takeaway
Doctors tested new cancer drugs on patients, and most of them were safe and showed some signs of helping people with cancer.
Methodology
The review summarizes phase I trial results of 11 drugs presented at the ASCO meeting, focusing on their safety, tolerability, and preliminary efficacy.
Limitations
The study primarily focuses on safety and dose-finding, not on definitive clinical efficacy.
Participant Demographics
Patients had various solid tumors and were typically heavily pre-treated with standard drug regimens.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website